ABCELLERA BIOLOGICS INC (ABCL)

CA00288U1066 - Common Stock

3.31  +0.18 (+5.75%)

After market: 3.3686 +0.06 (+1.77%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
375.2M
60.89%
485.4M
29.37%
38.025M
-92.17%
32.211M
-15.29%
43.988M
36.56%
69.3M
57.54%
57.216M
-17.44%
67.016M
17.13%
78.111M
16.56%
87.913M
12.55%
116.28M
32.27%
EBITDA
YoY % growth
218.9M
36.13%
244.4M
11.65%
-212.812M
-187.08%
-226.474M
-6.42%
-238.566M
-5.34%
-255.065M
-6.92%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
204.4M
31.03%
216.5M
5.92%
-237.207M
-209.56%
-316.497M
-33.43%
-263.534M
16.73%
-240.75M
8.65%
-286.908M
-19.17%
-291.389M
-1.56%
-292.272M
-0.30%
-293.696M
-0.49%
-269.28M
8.31%
Operating Margin
54.48%44.60%-623.82%-982.58%-599.10%-347.40%-501.45%-434.80%-374.18%-334.08%-231.58%
EPS
YoY % growth
0.47
-23.02%
0.50
6.38%
-0.52
-204.00%
-0.61
-16.71%
-0.69
-14.05%
-0.62
10.99%
-0.29
53.64%
-0.01
96.43%
0.35
3,500.00%
0.56
61.76%
-0.91
-261.82%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
-0.16
7.75%
-0.18
-27.50%
-0.19
-45.15%
-0.18
-5.00%
-0.18
-17.07%
Revenue
Q2Q % growth
7.731M
-15.78%
12.047M
21.03%
13.122M
79.19%
12.792M
96.59%
13.602M
75.94%
EBITDA
Q2Q % growth
-58.036M
-39.32%
-57.542M
-14.97%
-56.723M
-8.90%
-56.584M
-267.95%
-57.562M
0.82%
EBIT
Q2Q % growth
-68.728M
-4.05%
-65.297M
-18.95%
-67.034M
28.27%
-64.275M
31.38%
-64.312M
6.42%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-0.17
-70.00%
-0.15-0.02-9.89%
Q2 2024
Q2Q % growth
-0.13
-18.18%
-0.150.0211.08%
Q1 2024
Q2Q % growth
-0.14 -0.170.0317.44%
Q4 2023
Q2Q % growth
-0.17
-70.00%
-0.13-0.04-26.05%
Q3 2023
Q2Q % growth
-0.10
-225.00%
-0.140.0427.08%
Q2 2023
Q2Q % growth
-0.11
-450.00%
-0.130.0217.04%
Q1 2023
Q2Q % growth
-0.14
-125.93%
-0.140.00-1.14%
Q4 2022
Q2Q % growth
-0.10
-152.63%
-0.01-0.09-1,767.41%
Q3 2022
Q2Q % growth
0.08
200.00%
0.050.0372.64%
Q2 2022
Q2Q % growth
-0.02
-100.00%
-0.020.00-25.93%
Q1 2022
Q2Q % growth
0.54
45.95%
0.390.1537.82%
Q4 2021
Q2Q % growth
0.19
-56.82%
0.190.00-1.35%
Q3 2021
Q2Q % growth
-0.08 -0.05-0.03-49.39%
Q2 2021
Q2Q % growth
-0.01 0.08-0.09-112.61%
Q1 2021
Q2Q % growth
0.37 0.39-0.02-4.10%
Q4 2020
Q2Q % growth
0.44 0.62-0.18-29.28%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
6.507M
-1.39%
8.109M-1.602M-19.76%
Q2 2024
Q2Q % growth
7.323M
-27.18%
10.356M-3.033M-29.29%
Q1 2024
Q2Q % growth
9.954M
-18.36%
11.052M-1.098M-9.93%
Q4 2023
Q2Q % growth
9.179M
-57.31%
9.062M117K1.29%
Q3 2023
Q2Q % growth
6.599M
-93.49%
12.08M-5.481M-45.37%
Q2 2023
Q2Q % growth
10.056M
-78.09%
12.616M-2.56M-20.29%
Q1 2023
Q2Q % growth
12.192M
-96.15%
12.351M-159K-1.29%
Q4 2022
Q2Q % growth
21.5M
-84.57%
51.817M-30.317M-58.51%
Q3 2022
Q2Q % growth
101.4M
1,743.64%
76.453M24.947M32.63%
Q2 2022
Q2Q % growth
45.9M
66.30%
54.661M-8.761M-16.03%
Q1 2022
Q2Q % growth
316.6M
56.19%
224.14M92.46M41.25%
Q4 2021
Q2Q % growth
139.3M
-33.00%
124.49M14.81M11.90%
Q3 2021
Q2Q % growth
5.5M
-78.22%
12.848M-7.348M-57.19%
Q2 2021
Q2Q % growth
27.6M
146.43%
72.938M-45.338M-62.16%
Q1 2021
Q2Q % growth
202.7M 200.41M2.29M1.14%
Q4 2020
Q2Q % growth
207.9M
6,396.88%
201M6.9M3.43%
Q3 2020
Q2Q % growth
25.247M
200.23%
%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -4.83% 0% 1.54%
Revenue0% -34.67% 0% -6%